Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

TrendingWallStreet.com Brings you Coverage on NRF, NUVI, CYTR, and OPK

Accesswire December 12, 2013

Bullish Stocks Radar: CytRx Corporation, Echo Therapeutics Inc, Advanced Micro Devices, Inc, Baidu Inc

Accesswire December 11, 2013

CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial

Business Wire December 11, 2013

CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas

Business Wire December 10, 2013

CytRx Corporation to Present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11th, 2013

Business Wire December 4, 2013

CytRx to Present at the Sixth Annual LD MICRO "Main Event" Conference in Los Angeles on December 3, 2013

Business Wire November 26, 2013

MissionIR Releases Exclusive Audio Interview With CytRx Management

Marketwired November 7, 2013

CytRx Reports Further Positive Interim Data from Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas

Business Wire October 31, 2013

CytRx Reports 2013 Third Quarter Financial Results

Business Wire October 29, 2013

Global Phase 2b Clinical Data for CytRx's Aldoxorubicin to be Featured at the Connective Tissue Oncology Society Annual Meeting

Business Wire October 23, 2013

Five Star Equities Issues New Research Reports on ARIA, CGIX, CYTR and LPTN

Accesswire October 17, 2013

CytRx Announces Closing of Public Offering of Common Stock

Business Wire October 15, 2013

CytRx Announces Exercise of Underwriters' Over-Allotment Option

Business Wire October 11, 2013

Exclusive Video Interviews With CEOs Now on Equities.com: CGIX, CYTR, GWPH, HTBX, OPXA

Globe Newswire October 9, 2013

CytRx Announces Pricing of Public Offering of 10.0 Million Shares of Common Stock

Business Wire October 8, 2013

CytRx Announces Proposed Public Offering of Common Stock

Business Wire October 8, 2013

Five Star Equities Issues New Research Reports on CAR, CYTR, MRO and SIG

Accesswire September 30, 2013

OtcbbJournal.com, Where Savvy Traders Get Their Small-Cap Stock Research

Marketwired September 30, 2013

CytRx's New Aldoxorubicin Data Demonstrates Significant Advantages over Doxorubicin

Business Wire September 30, 2013

CytRx to Present at the Aegis Capital Corp. 2013 Healthcare Conference

Business Wire September 23, 2013